Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MSC plus mycophenolate mofetil for severe steroid-refractory acute graft-versus-host disease
NL-OMON44798Phase 3Active, not recruiting
- Sponsor
- HOVON
- Start
- Oct 2014
- Modality
- Small Molecules, Mesenchymal Stem Cells → Adult Stem Cells → Stem Cell Therapies → Cell Therapies
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of Provacel and mycophenolate mofetil in Acute Graft-Versus-Host Disease (aGvHD) (2 arms), sponsored by HOVON. Primary endpoint: Response rate at day 29. Started Oct 2014; status: active, not recruiting.
02
Drugs
Provacelmycophenolate mofetil
03
Conditions
Acute Graft-Versus-Host Disease (aGvHD)
Beyond the preview
Go deeper on NL-OMON44798.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON44798.